Spinal Cord Injury Clinical Trial
Official title:
Blood Flow Restriction Exercise to Improve Skeletal Muscle and Peripheral Vascular Function in Person With Spinal Cord Injuries
Spinal cord injuries (SCI) are among the most debilitating conditions an individual can sustain with the estimates of SCI incidence in the United States at 12,000 new cases per year. The loss of innervation to the tissues muscle below the level of the lesion results in reduced physical activity which leads to an array of secondary complications including muscle atrophy, cardiovascular and metabolic disease, obesity and vascular dysfunction. This further leads to exercise intolerance, reduced quality of life and depression. Although current rehabilitative programs focus on improving muscle strength in this population, the efficacy of these programs is challenged by the injury related motor impairment, which limits the exercise intensity and subsequent positive muscular adaptations. Therefore, development of an exercise program that promotes maximal muscular adaptations to light intensity exercise could greatly improve the efficacy of rehabilitation in the SCI population and help restore functional capacity and quality of life for these individuals. Blood flow restriction (BFR) exercise has shown tremendous promise for improving muscle size and strength in a variety of healthy and clinical populations, however the benefits of BFR exercise for those with SCI has not been established. Thus, the purpose of this Merit proposal is to conduct a comprehensive study that explores the benefits and risks of BFR exercise in the incomplete SCI population. In general individuals with chronic incomplete SCI will be recruited to partake in two 8-week training periods (20 sessions) that involve traditional knee extension/flexion exercise or knee extension/flexion exercise with blood flow restriction. There will be a series of measurements before and after the 8-week intervention to look at changes in muscle and vascular function. Specific Aim 1 will determine how the 8-weeks of BFR exercise influenced muscle strength (Biodex isokinetic dynamometer), muscle cross sectional area and volume (CTscan) and fatigue resistance. Specific Aim 2 will determine how this novel 8-week training intervention impacts peripheral vascular function. Specifically, changes in nitric oxide mediated endothelial function will be determined through tests of flow mediated dilation, changes in endothelial function of the microvascular network will be determined through assessments of reactive hyperemia and changes in arterial stiffness will be determined through measurements of pulse wave velocity. Specific Aim 3 will focus on the safety of BFR exercise for the SCI population. Those with SCI are at greater risk for thrombosis and DVT compared to able bodied individuals. Although unlikely, the introduction of temporary blood stasis during BFR exercise might augment this risk. Thus, the third aim of this study will be to determine changes in innate immune activation and thrombosis risk. Specifically, blood will be collected at multiple timepoints throughout the training intervention and analyzed for hypoxia-inducible factor 1-alpha, neutrophil extra cellular traps (which act as prothrombotic scaffolds), neutrophil-platelet aggregates and inflammatory cytokines. Ultimately, if the improvements in muscle and vascular function following BFR resistance exercise is greater than the traditional resistance exercise often performed in rehabilitation settings, without increasing risk for DVT, it should be incorporated into the long-term rehabilitation programs for Veterans with SCI.
Status | Recruiting |
Enrollment | 22 |
Est. completion date | August 31, 2024 |
Est. primary completion date | August 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - All participants must be between the ages of 18 and 75 years and have a medically stable incomplete spinal cord injury (AIS C or D) at least 1-year post injury - As the aim of this investigation is to focus on muscular and vascular adaptations to BFR exercise in the lower limbs, the level of injury must be between C3-L1 Exclusion Criteria: The following are the exclusion criteria: - Females that are pregnant - Individuals required to have ventilator assist devices - Individuals with significant active systemic disease, e.g. heart disease, renal failure/insufficiency and uncontrolled diabetes, uncontrolled hypertension and blood disorders that increase the risk for clot formation. - Individuals with chronic inflammatory disease states (i.e. multiple sclerosis or rheumatoid arthritis, Guillen-Barre syndrome, chronic inflammatory demyelinating disorder and acute amyotrophic lateral sclerosis) - Obese patients (>30% body fat based on skinfold measurements) - History of repeated DVTs or a DVT within the last year. - Individuals currently taking vasodilators - Individuals with orthopaedic limitations that would prevent them from performing knee extension/flexion exercise (with the exception of decreased strength due to the SCI) - Individuals with uncontrolled spasticity or a history of frequent autonomic dysreflexia |
Country | Name | City | State |
---|---|---|---|
United States | Louis Stokes VA Medical Center, Cleveland, OH | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in muscle cross sectional area | CTscan will be used to quantify cross sectional areal of several knee extensor and flexor muscles. | 0 and 56 days | |
Primary | Change in muscle strength | Using a biodex dynamometer we will quantify maximal knee extension strength and fatigue resistance. | 0 and 56 days | |
Primary | Change in vascular endothelial function | Flow mediated dilation (FMD)will be used to determine endothelial function in the popliteal arteries. | 0 and 56 days | |
Primary | Change in D-dimer | Blood will be sampled and analyzed for D-dimer, a marker of coagulation. | 0, 1, 28 and 56 days | |
Primary | Change in muscle fatigue resistance (percent decrease in maximal voluntary torque following fatigue protocol) | A fatigue knee extension protocol on a Biodex system 3 dynamometer will be used to quantify fatigue resistance of the quadriceps muscle group. Subjects will perform a maximal voluntary contraction before and after a 5 minute knee extension fatigue protocol. The relative decrease in maximal voluntary torque produced as a result of the fatiguing protocol (% decrease in torque) will provide an indication of fatigue resistance. | 0 and 56 days | |
Primary | Change in muscle volume | CTscan will be used to image the thigh from knee to pelvic. Muscle volume will be measured for several knee extensor and knee flexor muscles. | 0 and 56 days | |
Primary | Change in thrombin / antithrombin complex | Blood samples will be used for analysis of thrombin / antithrombin complex, a blood marker of coagulation. | 0, 1, 28 and 56 days | |
Primary | Change in prothrombin fragment 1.2 | Blood samples will be used for analysis of prothrombin fragment 1.2, a marker of coagulation. | 0, 1, 28 and 56 days | |
Secondary | Change in vessel stiffness | pulse wave velocity will be used to quantify changes in vessel stiffness in the lower limbs. | 0 and 56 days | |
Secondary | Change in interleukin (IL)-Beta | Blood will be sampled and analyzed for IL-Beta, a marker of inflammation. | 0, 1, 28 and 56 days | |
Secondary | Change in neutrophil-platelet aggregates | blood will be sampled and analyzed for Neutrophil-platelet aggregates to quantify neutrophil and platelet activity. | 0, 1, 28 and 56 days | |
Secondary | Change in Hypoxia-inducible factor 1-alpha (HIF-1 ) | HIF-1 is a constitutively expressed transcription factor that is degraded under normal oxygen tensions but stabilized with hypoxia. Under hypoxic conditions, stabilized HIF-1 translocates to the nucleus and promotes the transcription of a host of genes that enable the cell to adapt to the lack of oxygen. Aspects of the HIF-1 mediated hypoxic response include promoting angiogenesis and jump-starting inflammation. HIF-1 promotes neutrophil survival and increases neutrophil recruitment | 0, 1, 28 and 56 days | |
Secondary | Change in vascular endothelial growth factor (VEGF) | Blood samples will be analyzed for vascular endothelial growth factor (VEGF)by enzyme-linked immunosorbent assay | 0, 1, 28 and 56 days | |
Secondary | Change in reactive hyperemia | NIRS and Doppler/ultrasound imaging will be used to quantify reactive hyperemia following a 5 minute blood flow occlusion. | 0 and 56 days | |
Secondary | Change in interferon | Blood samples will be used for analysis of interferon (IFN), an inflammatory marker. | 0, 1, 28 and 56 days | |
Secondary | Change in C-reactive protein (CRP) | Blood samples will be used for analysis of C-reactive protein, an inflammatory marker. | 0, 1, 28 and 56 days | |
Secondary | Change in Interleukin 6 | Blood samples will be used for analysis of Interleukin 6 (IL-6), an inflammatory maker. | 0, 1, 28 and 56 days | |
Secondary | Change in NETosis | Blood samples will be used for analysis of NETosis (neutrophil extracellular traps). | 0, 1, 28 and 56 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02574572 -
Autologous Mesenchymal Stem Cells Transplantation in Cervical Chronic and Complete Spinal Cord Injury
|
Phase 1 | |
Recruiting |
NCT05941819 -
ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury
|
N/A | |
Completed |
NCT05265377 -
Safety and Usability of the STELO Exoskeleton in People With Acquired Brain Injury and Spinal Cord Injury
|
N/A | |
Recruiting |
NCT02331979 -
Improving Bladder Function in SCI by Neuromodulation
|
N/A | |
Completed |
NCT02777281 -
Safe and Effective Shoulder Exercise Training in Manual Wheelchair Users With SCI
|
N/A | |
Recruiting |
NCT02978638 -
Electrical Stimulation for Continence After Spinal Cord Injury
|
N/A | |
Completed |
NCT02161913 -
Comparison of Two Psycho-educational Family Group Interventions for Persons With SCI and Their Caregivers
|
N/A | |
Withdrawn |
NCT02237547 -
Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury
|
Phase 1/Phase 2 | |
Completed |
NCT02262234 -
Education Interventions for Self-Management of Pain Post-SCI: A Pilot Study
|
Phase 1/Phase 2 | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Completed |
NCT01642901 -
Zoledronic Acid in Acute Spinal Cord Injury
|
Phase 3 | |
Terminated |
NCT02080039 -
Electrical Stimulation of Denervated Muscles After Spinal Cord Injury
|
N/A | |
Terminated |
NCT01433159 -
Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury
|
Phase 2 | |
Completed |
NCT01471613 -
Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury
|
Phase 1/Phase 2 | |
Completed |
NCT02149511 -
Longitudinal Morphometric Changes Following SCI
|
||
Completed |
NCT01467817 -
Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI)
|
N/A | |
Completed |
NCT01025609 -
Dietary Patterns and Cardiovascular (CVD) Risk in Spinal Cord Injury (SCI) Factors In Individuals With Chronic Spinal Cord Injury
|
||
Terminated |
NCT01005615 -
Patterned Functional Electrical Stimulation (FES) Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury
|
Phase 1/Phase 2 | |
Completed |
NCT00663663 -
Telephone Intervention for Pain Study (TIPS)
|
N/A | |
Completed |
NCT01086930 -
Early Intensive Hand Rehabilitation After Spinal Cord Injury
|
Phase 3 |